Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075866 | 0.92 | FAAH (0.53) | FAAHCNR1CNR2 | |
| SCHEMBL4084842 | 0.92 | FAAH (0.53) | FAAHCNR1CNR2 | |
| SCHEMBL4075655 | 0.88 | CNR1 (0.51) | FAAHCNR1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4087343 | 0.83 | CYP2C19 (0.41) | FAAHCNR1NAMPTCNR2 | |
| SCHEMBL4075813 | 0.81 | CNR1 (0.46) | FAAHHPGDCNR1NAMPTCNR2 | |
| SCHEMBL4075572 | 0.80 | CNR1 (0.52) | FAAHCNR1CNR2 | |
| SCHEMBL5481564 | 0.80 | FAAH (0.43) | FAAHCNR1CNR2 | |
| SCHEMBL4082474 | 0.79 | FAAH (0.49) | FAAHCNR1CNR2 | |
| SCHEMBL4089341 | 0.79 | CNR1 (0.52) | FAAHCNR1CNR2 | |
| SCHEMBL29574730 | 0.79 | CNR1 (0.52) | FAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-7504522-B2 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | CNR1, CNR2, GPR119 | FAAH 8/4885HPGD 1867/4885ALDH1A1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.